Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) FCF Margin (2018 - 2025)

Sunshine Biopharma's FCF Margin history spans 9 years, with the latest figure at 18.83% for Q4 2025.

  • For Q4 2025, FCF Margin rose 1773.0% year-over-year to 18.83%; the TTM value through Dec 2025 reached 15.16%, up 2550.0%, while the annual FY2025 figure was 15.16%, 2550.0% up from the prior year.
  • FCF Margin reached 18.83% in Q4 2025 per SBFM's latest filing, down from 7.81% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 7.81% in Q3 2025 to a low of 1192.65% in Q3 2021.
  • Average FCF Margin over 5 years is 309.58%, with a median of 51.38% recorded in 2024.
  • The largest YoY upside for FCF Margin was 114713bps in 2021 against a maximum downside of -62889bps in 2021.
  • A 5-year view of FCF Margin shows it stood at 366.68% in 2021, then skyrocketed by 83bps to 61.95% in 2022, then soared by 52bps to 30.04% in 2023, then fell by -22bps to 36.56% in 2024, then skyrocketed by 48bps to 18.83% in 2025.
  • Per Business Quant, the three most recent readings for SBFM's FCF Margin are 18.83% (Q4 2025), 7.81% (Q3 2025), and 15.23% (Q2 2025).